MedKoo Cat#: 464182 | Name: Ofloxacin-d8 HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ofloxacin-d8 is intended for use as an internal standard for the quantification of ofloxacin by GC- or LC-MS. Ofloxacin is a broad-spectrum fluoroquinolone antibiotic that prevents supercoiling of bacterial chromosomes by DNA gyrase. It is active against Gram-positive and Gram-negative bacteria with MIC90s ranging from 0.39 to 3.13 μg/ml for clinical isolates of S. aureus, S. epidermidis, S. pyogenes, and S. faecalis and ≤0.78 μg/ml for N. gonorrhoeae and various species of Enterobacteriaceae. Ofloxacin is active in vivo, with ED50 values ranging from 0.7 to 75.1 mg/kg in infected mice. Formulations containing ofloxacin have been used to treat urinary tract infections, gonorrhea, prostatitis, and gastroenteritis.

Chemical Structure

Ofloxacin-d8 HCl
Ofloxacin-d8 HCl
CAS#unknown

Theoretical Analysis

MedKoo Cat#: 464182

Name: Ofloxacin-d8 HCl

CAS#: unknown

Chemical Formula: C18H13D8ClFN3O4

Exact Mass: 405.1707

Molecular Weight: 405.88

Elemental Analysis: C, 53.27; H, 7.20; Cl, 8.73; F, 4.68; N, 10.35; O, 15.77

Price and Availability

Size Price Availability Quantity
5mg USD 900.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Ofloxacin-d8 HCl; Ofloxacin d8 HCl; Ofloxacin-d8 hydrochloride; Ofloxacin d8 hydrochloride;
IUPAC/Chemical Name
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl-2,2,3,3,5,5,6,6-d8)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hydrochloride
InChi Key
CAOOISJXWZMLBN-JCYLEXHWSA-N
InChi Code
InChI=1S/C18H20FN3O4.ClH/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H/i3D2,4D2,5D2,6D2;
SMILES Code
FC1=CC2=C3C(OCC(N3C=C(C2=O)C(O)=O)C)=C1N4C([2H])(C([2H])(N(C([2H])(C4([2H])[2H])[2H])C)[2H])[2H].Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
to be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Ofloxacin-d8 (hydrochloride) is deuterium labeled Ofloxacin (hydrochloride).
In vitro activity:
Chondrocytes from juvenile rabbit joints were incubated with ofloxacin at concentrations of 0, 5, 10, 20, 40 and 80 microg/ml, respectively. It was observed that ofloxacin induced a concentration-dependent increase in intracellular reactive oxygen species production, which may be an early mediator of ofloxacin cytotoxicity. Similarly, ofloxacin resulted in a significant lipid peroxidation, revealed by a concentration-dependent increase in the level of thiobarbituric acid reactive substances. Reference: Eur J Pharmacol. 2010 Jan 25;626(2-3):146-53. https://pubmed.ncbi.nlm.nih.gov/19818344/
In vivo activity:
The antiviral activity of ofloxacin, a new quinolone derivative, against vaccinia virus (VV), herpes simplex virus (HSV) and influenza virus (InfV) was evaluated in both in vitro and in vivo experiments. As a result, ofloxacin showed inhibitory activity against VV in cultured mammalian cells, and prevented formation of pox tail lesions in VV-infected mice. The antiviral activity of ofloxacin assessed by VV tail-lesion test was strongest when administered to mice through the oral route daily for five consecutive days post-infection. Reference: Antiviral Res. 1987 Oct;8(3):103-13. https://pubmed.ncbi.nlm.nih.gov/2827566/
Solvent mg/mL mM
Solubility
To be determined 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 405.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Resch MD, Resch BE, Csizmazia E, Imre L, Németh J, Révész P, Csányi E. Permeability of human amniotic membrane to ofloxacin in vitro. Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1024-7. doi: 10.1167/iovs.09-4254. Epub 2009 Sep 24. PMID: 19797205. 2. Li Q, Peng S, Sheng Z, Wang Y. Ofloxacin induces oxidative damage to joint chondrocytes of juvenile rabbits: excessive production of reactive oxygen species, lipid peroxidation and DNA damage. Eur J Pharmacol. 2010 Jan 25;626(2-3):146-53. doi: 10.1016/j.ejphar.2009.09.044. Epub 2009 Oct 7. PMID: 19818344. 3. Grosset JH, Guelpa-Lauras CC, Perani EG, Beoletto C. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis. 1988 Jun;56(2):259-64. PMID: 3045223. 4. Ikeda S, Yazawa M, Nishimura C. Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative. Antiviral Res. 1987 Oct;8(3):103-13. doi: 10.1016/0166-3542(87)90064-7. PMID: 2827566.
In vitro protocol:
1. Resch MD, Resch BE, Csizmazia E, Imre L, Németh J, Révész P, Csányi E. Permeability of human amniotic membrane to ofloxacin in vitro. Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1024-7. doi: 10.1167/iovs.09-4254. Epub 2009 Sep 24. PMID: 19797205. 2. Li Q, Peng S, Sheng Z, Wang Y. Ofloxacin induces oxidative damage to joint chondrocytes of juvenile rabbits: excessive production of reactive oxygen species, lipid peroxidation and DNA damage. Eur J Pharmacol. 2010 Jan 25;626(2-3):146-53. doi: 10.1016/j.ejphar.2009.09.044. Epub 2009 Oct 7. PMID: 19818344.
In vivo protocol:
1. Grosset JH, Guelpa-Lauras CC, Perani EG, Beoletto C. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis. 1988 Jun;56(2):259-64. PMID: 3045223. 2. Ikeda S, Yazawa M, Nishimura C. Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative. Antiviral Res. 1987 Oct;8(3):103-13. doi: 10.1016/0166-3542(87)90064-7. PMID: 2827566.
1: Zhang S, Liu C, Yang D, Ruan J, Luo Z, Quan P, Fang L. Mechanism insight on drug skin delivery from polyurethane hydrogels: roles of molecular mobility and intermolecular interaction. Eur J Pharm Sci. 2021 Mar 2:105783. doi: 10.1016/j.ejps.2021.105783. Epub ahead of print. PMID: 33667662. 2: Novotny LA, Chiang T, Goodman SD, Elmaraghy CA, Bakaletz LO. Humanized Anti- DNABII Fab Fragments Plus Ofloxacin Eradicated Biofilms in Experimental Otitis Media. Laryngoscope. 2021 Mar 5. doi: 10.1002/lary.29497. Epub ahead of print. PMID: 33666254.